Clinical Trial

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

Study acronym: SAFYR
Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-22.
Status change: Recruiting → Completed 2026-04-17
Trial Details
NCT Number NCT06998004
Lead Sponsor AstriVax Therapeutics
Conditions Yellow Fever, Rabies
Enrollment 112 participants
Start Date 2024-06-16
Primary Completion 2026-01-26 (estimated)
Study Completion 2026-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-22